2012 CANCER ANNUAL REPORT

Transcription

1 CANCER ANNUAL REPORT

2 CANCER REGISTRY SUMMARY CANCER REGISTRY SUMMARY The cancer registry is an essential component of the Commission on Cancer (CoC) accredited cancer program. The Cancer Program at Mercy Memorial Hospital System is a strategic partner with CHAMPS Oncology Data Services who staff the registry with credentialed Certified Tumor Registrars and CoC consultants. CHAMPS personnel help programs achieve their goals by collecting and reporting quality cancer data in support of their business planning and outreach initiatives. Data collected by the cancer registry is an invaluable tool in the fight against cancer. The registry collects demographic- and disease-specific data elements on each cancer patient presenting for diagnosis or treatment. The information collected is utilized by physicians, administration and other health care professionals. Among the many uses are: MEASURING quality outcomes TRACKING community outreach initiatives SUPPORTING clinical, diagnostic and treatment research EVALUATING the effectiveness of current treatment modalities PRESENTING data for individualized patient treatment planning SUBMITTING to local and national databases for incidence and outcome comparison DATA SUMMARY Mercy Memorial Hospital System s cancer registry accessioned 4 new cases ( of them analytic) for. The following graph illustrates the most frequent primary sites (analytic cases only) seen at this facility compared to the top five sites statewide for Breast Lung Prostate Bladder Colon Prostate Lung Breast Colon Bladder MERCY MEMORIAL HOSPITAL SYSTEM TOP 5 SITES *8 STATE OF MICHIGAN TOP 5 SITES *8 is the most recent data year available.

3 MALE/FEMALE TOP 5 SITES The top five sites for all patients at Mercy Memorial are breast, lung, prostate, bladder and colon. The gender distribution for those sites is represented in the graph below. ONCOLOGY PATIENT DEMOGRAPHICS The majority (99 percent) of the patients presenting to Mercy Memorial Hospital System reside in Monroe County. This is represented by the following chart below. NUMBER OF CASES 5 4 COUNTY OF RESIDENCE % 99% Breast Lung Prostate Bladder Colon Female Male Other Monroe MERCY MEMORIAL BREAST TIME STUDY As part of our initiative to deliver high-quality, patient-centered care at Mercy Memorial, we are continuously looking at data and benchmarking our outcomes to national data. A trend that has emerged in recent years is tracking the time (in days elapsed) from when a patient receives an abnormal mammogram to the day a patient receives diagnostic confirmation through a biopsy. The national benchmark is 4 days. In, the average number of days a woman had to wait for a biopsy at Mercy Memorial was. days. The cancer committee agreed this was not acceptable and an initiative was started to reduce the number of days a woman had to wait before undergoing a biopsy. In, a Breast Imaging Navigator position was created to help coordinate the scheduling of biopsies in a timely manner as well as answering any questions patients may have with regards to the diagnostic process. Since the implementation of this role, the average number of days has been reduced to only 8.98 in. The data will continue to be evaluated each year to ensure Mercy Memorial is offering the highest-quality patient care from before diagnosis to treatment and through survivorship. See study results on page 4.

4 The following table details the number of analytic cases by primary site for. Total Stg Stg I Stg II Stg III Stg IV n/a Unk MERCY MEMORIAL BREAST TIME STUDY (CONTINUED) PRIMARY SITE Total Time elapsed (in days) between abnormal radiology and date of incisional Breast Lung & Bronchus Prostate Urinary Bladder Colon Excluding Rectum Hodgkin s Lymphoma Other Endocrine Including Thymus Other Male Genital Organs core biopsy or date of first treatment (whichever occurred first) TIMEFRAME: Jan., Dec., Corpus & Uterus, NOS Rectum & Rectosigmoid 5 5 Stomach Anus NUMBER OF CASES: 54 Non-Hodgkin s Lymphoma Nodal Oral Cavity & Pharynx Vulva Multiple Myeloma Brain AVERAGE NUMBER OF DAYS ELAPSED BY MONTH IN : January. 5 Leukemia Kidney & Renal Pelvis 5 Soft Tissue (Excluding Heart) February March.. 8 Other Nervous System Non-Hodgkin s Lymphoma Extranodal Melanoma Skin Thyroid Liver Esophagus Larynx Small Intestine Other Digestive Nose, Nasal Cavity & Middle Ear April May June July August September October Ovary Pancreas Mesothelioma All Other November December.. FOLLOW-UP Meaningful survival and outcome measures require reliable tracking of disease, recurrence and vital status for the lifetime of each patient record. Accurate follow-up data enables Mercy Memorial Hospital to compare outcomes with regional, state or national statistics. The successful follow-up rate at Mercy Memorial since the established registry reference year () is 95 percent. The rate is well above the CoC requirement of 9 percent. YEARLY AVERAGE (IN DAYS):

5 CANCER REGISTRY SUMMARY CANCER REGISTRY SUMMARY Each case accessioned into the registry database is assigned a class of case based on the location of initial diagnosis and/or treatment, which allows for the evaluation of referral patterns. Class of case analysis can also be a valuable tool in the planning and allocation of resources at the facility. CLASS OF CASE DEFINITIONS AND DISTRIBUTION Analytic (n = ) / Non-Analytic (n = ) CLASS N = Diagnosis at the accessioning facility and the entire first course of treatment was performed elsewhere or the decision not to treat was made at another facility. CLASS N = Initial diagnosis at the reporting facility or in a staff physician s office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS (Not otherwise specified). Initial diagnosis in staff physician s office AND part of first course treatment was done at the reporting facility. Initial diagnosis in staff physician s office AND all first course treatment or a decision not to treat was done at the reporting facility. Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility. 4 Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility. CLASS N = Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS. Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility. Initial diagnosis elsewhere AND all first course treatment or decision not to treat was done at the reporting facility. Non-Analytic (n = ) CLASS N = Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, staging workup after initial diagnosis elsewhere). Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care. Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence. Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (these cases are not reported). 5 Case diagnosed before program s Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility. Case diagnosed before program s Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility. 8 Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death. CLASS 4 N = 4 Diagnosis AND all first course treatment given at the same staff physician s office. 4 Diagnosis AND all first course treatment given at two or more different staff physicians offices. 4 Nonstaff physician or non-coc accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility). 4 Pathology or other lab specimens only. 49 Death certificate only. 5

6 CANCER TREATMENT A COMPREHENSIVE APPROACH TO CANCER CARE The Mercy Memorial Hospital System cancer treatment program is a collective effort of dozens of specialists, nurses, critical care coordinators, radiologists, pathologists, oncologists and other care providers. Through this collaboration of experts, patients can receive a diagnosis and treatment for all types of cancer without leaving Monroe County. Mercy Memorial s comprehensive cancer treatment program uses the strength of interdisciplinary teams, one-on-one patient consults, advanced medical imaging and designated inpatient beds. MONROE CANCER CENTER In June, the Monroe Cancer Center opened. This joint venture partnership with Mercy Memorial, Karmanos Cancer Institute and ProMedica has brought high-quality, patient-centered care under one roof. As a result, residents in Monroe and the surrounding communities no longer have to travel an hour or more for radiation treatment, patients have improved access to the latest cancer treatments, including clinical trials, and patients, their families and other loved ones impacted by cancer have access to important support resources. RADIATION ONCOLOGY: Radiation services are provided by the Karmanos Cancer Institute team, who are leaders in radiotherapy delivery. MEDICAL ONCOLOGY: Chemotherapy treatments are provided by Toledo Clinic medical and hematologic oncologists. CLINICAL TRIALS: Qualified patients at the Monroe Cancer Center have access to the latest clinical trials, which are currently being offered through Mercy Memorial Hospital System. The $5 million facility is almost, square feet, including more than, feet of radiation oncology treatment areas. The center also includes physician offices, laboratory services, an American Cancer Society wig bank and a community room for education, workshops and support groups. MERCY MEMORIAL CANCER CONNECTION The Cancer Connection, located inside the Monroe Cancer Center, provides hands-on, nonclinical assistance to residents of Monroe County who have been diagnosed with cancer. 8

7 CANCER SERVICES Mercy Memorial s cancer treatment program includes: detection programs support services We help provide peace of mind for over one hundred patients each month, said Donna Hwang, coordinator of Mercy Memorial Cancer Connection. Our staff of more than 5 volunteers provides a wide range of services. These cancer support services are free to qualifying patients in Monroe and include discounted and free nutritional supplements (with physician order), transportation within a 5-mile radius to cancerrelated appointments, assistance with fuel costs, mastectomy supplies, and medical supplies and equipment such as shower chairs or wheelchairs. Hwang and her staff also are there when patients and their families need additional guidance. Sometimes, patients and families just need to talk to somebody, so we ll meet with them privately, Hwang said. In addition, we offer referrals to other resources, classes and support groups.

8 8 North Macomb Street Monroe, Michigan 48 (4) 4-84 mercymemorial.org Annette S. Phillips, FACHE President and Chief Executive Officer Michael Charboneau, Jr., D.O., Chairman Charu Trivedi, M.D., Cancer Liaison Physician John E. Kibble, Executive Champion Joan Pierson, M.S., R.T. (R) (T), Oncology Program Manager Celeste Batchev, M.D. Donna Booth Andrea Bridson Megan Coriell, R.H.I.A., C.T.R. Larry Csokasy, L.M.S.W. Kristin Ferreira, O.T.R.L. Gail Gedelian, R.T. (R) (M) (BD) Donna Hwang Navin Jain, M.D. Tammy Knapp Andre Konski, M.D., M.B.A., M.S., F.A.C.R. Larry Lyons, M.Div., C.B.C. Tina Melonakos, Pharm.D. Cindy Miller, B.S., R.R.T. Ramachandran Nair, M.D. Sandra Oetting, R.N., B.C., M.S.N., N.P., C.H.P.N. Debra Osentoski, R.N., B.S.N., O.C.N., C.B.C.N. Brian Paules, B.S., C.C.T. Karyn Rowe, R.D. Mary Russ, R.N., A.C.M. Gehring Sauter, M.D. Joyce Shankleton, M.S.A., R.N. Mark Sherrard, D.O. Janet Spare, R.N. Jennifer Strohmeyer, M.S.N., R.N. Jackie Swearingen Karen Whitmire, R.N.